Tongrentang Angong Niuhuang Wan
PreclinicalSmall molecule
Tongrentang Angong Niuhuang Wan is one of 54 small molecule programs targeting Brain Injury. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
64 competitors in Brain Injury
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Keppra
UCBApproved
Namenda
AbbVieApproved
Buspar
Bristol-Myers SquibbApproved
Celexa
AbbVieApproved
Vimpat
UCBApproved
Exelon
NovartisApproved
Vyvanse
TakedaApproved
Rozerem
TakedaApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHuaqiu Zhang